Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of “Hold” by Brokerages

Agenus Inc. (NASDAQ:AGEN) has been given an average rating of “Hold” by the six brokerages that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $8.75.

Several research analysts recently commented on AGEN shares. Robert W. Baird reduced their target price on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, March 12th. StockNews.com raised shares of Agenus from a “sell” rating to a “hold” rating in a report on Friday, March 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Agenus in a research note on Tuesday, March 18th.

Agenus Stock Performance

NASDAQ AGEN opened at $1.60 on Wednesday. Agenus has a twelve month low of $1.55 and a twelve month high of $19.69. The stock has a market cap of $40.49 million, a PE ratio of -0.14 and a beta of 1.23. The firm has a 50-day simple moving average of $2.85 and a 200 day simple moving average of $3.53.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to the consensus estimate of $30.09 million. Research analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Corton Capital Inc. acquired a new stake in shares of Agenus during the 4th quarter worth about $36,000. Virtu Financial LLC bought a new stake in Agenus during the fourth quarter worth about $51,000. Apollon Wealth Management LLC bought a new stake in Agenus during the fourth quarter worth about $55,000. EP Wealth Advisors LLC acquired a new stake in shares of Agenus during the third quarter worth approximately $55,000. Finally, Bank of Montreal Can acquired a new position in shares of Agenus in the 4th quarter worth approximately $69,000. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.